We compared the TuPro melanoma cohort (n = 98), which received multi-omics–guided selection of adjuvant, standard of care and beyond standard-of-care therapies in patients with advanced melanoma, to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results